Fig. 6
From: The genomic alterations in glioblastoma influence the levels of CSF metabolites
Pairwise comparisons of carnitine compound levels in CSF of control, GBM-TP53-mutant, and GBM-TP53-wildtype patients. (A) carnitine, (B) propionylcarnitine, (C) 2-methylbutyrylcarnitine, (D) isobutyryl-L-carnitine, and (E) deoxycarnitine. The abundance of carnitine compounds was not significantly different between control and GBM-TP53-mutant groups except for 2-methylbutyrylcarnitine (C). Metabolite abundance was significantly different between control and GBM-TP53-wildtype samples for all 5 carnitine compounds